Immunogenetic associations of scleroderma‐related antinuclear antibodies

Arthritis & Rheumatism

Volumn 33, Issue 5, 1990, Pages 657-665

  Genth, Ekkehard ^a,b,d,f   Mierau, Rudolf ^b,d,f   Genetzky, Petra ^b,d,f   Von Mühlen, Carlos A ^b,d,e,f   Kaufmann, Sidonie ^b,c,d,f   Wilmowsky, Hubertus Von ^b,c,d,f   Meurer, Michael ^b,d,f   Krieg, Thomas ^b,d,f   Pollmann, Hans‐Joachim ^b,c,d,f   Hartl, Paul Walter ^b,c,d,f  

^a Research Department   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Clinic and Research Institute for Rheumatic Diseases   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^f Pontificia Universidade Catolica ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCLERODERMA;

ANTIBODIES, ANTINUCLEAR; COMPARATIVE STUDY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-DR ANTIGENS; HUMAN; IMMUNOGENETICS; SCLERODERMA, SYSTEMIC; SUPPORT, NON-U.S. GOV'T;

EID: 0025345395     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780330508     Document Type: Article

References (63)

1. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti‐centromere antibody and its relationship to CREST syndrome.
2. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.
3. Zentromerantikörper und Antikörper gegen Scl‐70 bei progressiver systemischer Sklerose.
4. Profile of antinuclear antibodies in progressive systemic sclerosis (abstract).
5. High titers of autoantibodies to topoisomerase I (Scl‐70) in sera from scleroderma patients.
6. Complexity of antinuclear antibodies in scleroderma (abstract).
7. Antinuclear antibody with distinct specificity for polymyositis.
8. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients.
9. The CREST syndrome: a distinct serologic entity with anticentromere antibodies.
10. Frequency and clinical significance of anticentromere and anti scl‐70 antibodies in an English connective tissue disease population.
11. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
12. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis.
13. Characterization of centromere (kinetochore) antigen reactive with sera of patients with a scleroderma variant (CREST syndrome).
14. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.
15. Clinical relevance of PM‐1 antibody and physiochemical characterization of PM‐1 antigen.
16. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma).
17. Association of HLA antigen A9 with progressive systemic sclerosis (scleroderma).
18. HLA antigens and scleroderma.
19. The association of HLA‐B8 with visceral disease in systemic sclerosis.
20. Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response.
21. Scleroderma: possible significance of silent alleles at the C4B locus.
22. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma).
23. HLA‐D antigens in progressive systemic sclerosis (scleroderma).
24. DR antigens in systemic sclerosis: lack of clinical correlations.
25. HLA antigens, autoantibodies and clinical subsets in scleroderma.
26. HLA‐DR antigens in progressive systemic sclerosis (scleroderma).
27. Increased prevalence of DRw3 in the CREST syndrome.
28. Increased frequency of HLA‐DR5 in scleroderma.
29. A strong association between null alleles at the C4A locus in the major histocompatibility complex and systemic sclerosis.
30. Recherche d'une association entre antigenes HL‐A et sclerodermie systemique.
31. HLA antigens in progressive systemic sclerosis (scleroderma) (letter).
32. Histocompatibility antigens in progressive systemic sclerosis (scleroderma).
33. Lack of association of HLA‐DR antigens with progressive systemic sclerosis (scleroderma).
34. Systemic sclerosis (scleroderma): clinical genetic, and serologic subsets.
35. Clinical evaluation and HLA‐typing of patients with scleroderma and anticentromere antibodies (ACA) (abstract).
36. Autoantibodies and immunogenetics in 30 patients with systemic sclerosis and their families.
37. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma).
38. Polymyositis and dermatomyositis.
39. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
40. The Copenhagen criteria for Sjögren's syndrome.
41. Microdroplet testing for HLA‐A, ‐B, ‐C, and ‐D antigens.
42. Isolation of B and T lymphocytes by nylon fiber columns.
43. Genetic studies on human immunoglobulins
44. Increased frequency of Gm(1,2;21) phenotype in HLA‐DR4 positive seropositive rheumatoid arthritis.
45. On estimating the relation between blood group and disease.
46. Immunogenetics of rheumatoid arthritis.
47. Putative amino acid sequence of HLA‐DRB chain contributing to rheumatoid arthritis susceptibility.
48. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes.
49. Class II major histocompatibility complex gene sequences in rheumatoid arthritis: the third diversity regions of both DRβ1 genes in the two DR1, DRw10‐positive individuals specify the same inferred amino acid sequence as the DRβ1 and DRβ2 genes of a DR4 (Dw14) haplotype.
50. Immunogenetics of rheumatoid arthritis.
51. Anticorps anticentromere au cours d'une polyarthrite rheumatoide avec syndrome de Sjögren, sans element du syndrome CREST.
52. HLA‐DQβ gene contributes to susceptibility and resistance to insulindependent diabetes mellitus.
53. Identification of susceptibility loci for insulin‐dependent diabetes mellitus by trans‐racial gene mapping.
54. A molecular basis for genetic susceptibility to insulin‐dependent diabetes mellitus.
55. An increased risk of insulin‐dependent diabetes mellitus (IDDM) among HLA‐DR4, DQw8/DRw8, DQw4 heterozygotes.
56. Dermatomyositis in 6 patients without initial muscle involvement.
57. HLA‐D related (DR) antigens in various kinds of myositis.
58. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
59. HLA‐DR4 and Gm(1,3;5,21) are associated with U1‐nRNP antibody positive connective tissue disease.
60. HLA and immunoglobulin allotypes in mixed connective tissue disease.
61. Serologic subsets in lupus erythematosus: an examination of autoantibodies in relationship to clinical features of disease and HLA antigens.
62. The Jo‐1 antibody system in myositis: relationships to clinical features and HLA.